Demos Could Result From ‘Most Favored Nation’ Order
The Trump administration’s long-awaited executive order that seeks to tie U.S. drug prices to costs in other countries may represent more presidential campaign talking points than real policy that will take effect quickly. But analysts expect that the overarching issue of drug pricing will stick around, regardless of which candidate wins on Nov. 3.
For example, the executive order signals that the administration could pursue price caps for select Medicare Part B and D drugs in a possible second term. The order calls for demonstration projects to test “most favored nation” pricing in Parts B and D.
© 2023 MMIT